Eculizumab
- Generic Name
- Eculizumab
- Brand Names
- Soliris, Epysqli, Bekemv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219685-50-4
- Unique Ingredient Identifier
- A3ULP0F556
- Background
Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
...
- Indication
Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD). It is also indicated in EU to treat PNH in both adult and pediatric patients.
- Associated Conditions
- Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT04702568
- Locations
- 🇬🇧
Study Center, London, United Kingdom
Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 97
- Registration Number
- NCT04558918
- Locations
- 🇺🇸
City Of Hope National Med Center City of Hope Medical Center, Duarte, California, United States
🇺🇸Augusta University Georgia Patient Treatment, Augusta, Georgia, United States
🇺🇸Univ Cali Irvine ALS Neuromuscular, Orange, California, United States
A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 204
- Registration Number
- NCT04434092
- Locations
- 🇵🇱
MTZ Clinical Research Powered by Pratia, Warszawa, Poland
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico
🇵🇹Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT04432584
- Locations
- 🇫🇷
Institut Paoli Calmette; Service d'Hématologie Clinique, Marseille, France
🇬🇷General Hospital of Athens LAIKO, Athens, Greece
🇬🇷Attikon University General Hospital, Chaidari, Greece
CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort
- First Posted Date
- 2020-04-15
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 120
- Registration Number
- NCT04346797
- Locations
- 🇫🇷
Réanimation médicale, Paris, France
🇫🇷Saint Louis, Paris, Ile De France, France
🇫🇷saint Louis, Paris, France
Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
- Conditions
- Interventions
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04320602
- Locations
- 🇬🇧
Clinical Study Site, London, United Kingdom
🇬🇧Research Site, London, United Kingdom
Eculizumab (Soliris) in Covid-19 Infected Patients
- Conditions
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Hudson Medical
- Registration Number
- NCT04288713
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
- Conditions
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04155424
- Locations
- 🇪🇸
Clinical Trial Site, Sevilla, Spain
🇪🇸Research Site, Esplugues de Llobregat, Spain
The Use of Eculizumab in HELLP Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-09-25
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 3
- Registration Number
- NCT04103489
- Locations
- 🇺🇸
The Johns Hopkins University, Baltimore, Maryland, United States
A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH
- Conditions
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT03818607
- Locations
- 🇮🇪
Saint James's Hospital, Dublin, Ireland
🇨🇿Fakultní Nemocnice Ostrava, Ostrava-Poruba, Czechia
🇨🇿Fakultní Nemocnice Brno, Brno, Jihormoravsky KRAJ, Czechia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.